BMRN Q3 2025 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$776M+4.1% YoY

Gross Profit

$636M82.0% margin

Operating Income

-$47M-6.0% margin

Net Income

-$31M-4.0% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

-6.0%

Cash Flow

Operating Cash Flow

$369M

Free Cash Flow

$340M

Stock-Based Comp.

$49M

Balance Sheet

Total Assets

$7.6B

Total Liabilities

$1.6B

Stockholders' Equity

$6.1B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$776M	$746M	+4.1%
Gross Profit	$636M	$557M	+14.1%
Operating Income	-$47M	$114M	-141.0%
Net Income	-$31M	$106M	-129.0%

Revenue Segments

Product

$761M98%

Royalty And Other

$15M2%